Stockscreener 앱 받기
90.31
5.18%
4.45
시간 외 거래:
94.37
4.06
+4.50%
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
5 Most Promising Stocks Under $100 to Buy - Insider Monkey
First FDA-approved drug for rare weight-gain disorder clears in US - Stock Titan
Rhythm Awaits FDA Decision On Expanded Use Of Imcivree In Hypothalamic Obesity - RTTNews
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - MSN
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism - Insider Monkey
H.C. Wainwright cuts Rhythm Pharmaceuticals stock price target on trial miss - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) expected to beat earnings estimates: Should you buy? - MSN
HC Wainwright Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals: EMANATE Setback but Validated MC4R Mechanism and Pipeline Optionality Support Lowered $100 Buy Rating - TipRanks
HC Wainwright & Co. Lowers Price Target for Rhythm Pharmaceutica - GuruFocus
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR) - The Globe and Mail
Focus Shifts To Rhythm’s Imcivree Hypothalamic Obesity Opportunity After Phase III Miss - Citeline News & Insights
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Weakness And Strong Long Term Returns - Yahoo Finance
Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its 4x Three Year Surge? - simplywall.st
Wall Street Recap: Can Rhythm Pharmaceuticals Inc ride the EV waveSwing Trade & Daily Profit Maximizing Tips - baoquankhu1.vn
Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote, News & History - Benzinga
RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaini - GuruFocus
Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat - Investor's Business Daily
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $131.00 at Citigroup - MarketBeat
Post-Emanate, Rhythm’s next Imcivree news aHO lot better? - BioWorld MedTech
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $130.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Rhythm Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Citizens Lowers Price Target for Rhythm Pharmaceuticals (RYTM) W - GuruFocus
Citizens Jmp Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $152.00 - MarketBeat
Needham cuts Rhythm Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Analyst Rating Update: Price Targe - GuruFocus
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaining Overweight Rating | RYTM Stock News - GuruFocus
Needham & Company LLC Lowers Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $130.00 - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $139.00 Price Target at Bank of America - MarketBeat
Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED) - Benzinga
RYTM: Needham Maintains Buy Rating While Lowering Price Target | - GuruFocus
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints - Benzinga
RBC Lowers Price Target on Rhythm Pharmaceuticals to $130 From $140, Keeps Outperform, Speculative Risk - marketscreener.com
Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Aquatic Capital Management LLC - MarketBeat
Stocks Showing Improving Market Leadership: Rhythm Pharmaceuticals Earns 81 RS Rating - Investor's Business Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE TrialSlideshow (NASDAQ:RYTM) 2026-03-17 - Seeking Alpha
Rhythm Pharma shares fall as obesity drug trial fails to meet main goal - Investing.com Canada
Stifel reiterates Rhythm Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial - Bitget
Rhythm Pharmaceuticals Reports Mixed Phase 3 EMANATE Results - TipRanks
Rhythm Pharmaceuticals (RYTM) Shares Results from EMANATE Trial - GuruFocus
Phase 3 EMANATE trial miss at Rhythm Pharmaceuticals (Nasdaq: RYTM) - Stock Titan
Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares - Stock Titan
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial - marketscreener.com
Obesity drug trial misses goal, yet some patients cut BMI by 9.7% - Stock Titan
Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision (NASDAQ:RYTM) - Seeking Alpha
First Light Asset Management LLC Takes $18.23 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Cinctive Capital Management LP Sells 35,781 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Checkpoint Capital L.P. Has $77.13 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Algert Global LLC Increases Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals Q4 2025 earnings preview - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Integral Health Asset Management LLC Increases Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Early FDA, Japan Filings For Setmelanotide In Hypothalamic Obesity Might Change The Case For Investing In Rhythm Pharmaceuticals (RYTM) - Sahm
Institution Moves: Is Rhythm Pharmaceuticals Inc vulnerable to short sellers2026 Price Targets & Long Hold Capital Preservation Plans - baoquankhu1.vn
Wells Fargo Maintains Overweight, Raises Price Target for RYTM t - GuruFocus
Wells Fargo raises Rhythm Pharmaceuticals price target on revenue By Investing.com - Investing.com Australia
Wells Fargo raises Rhythm Pharmaceuticals price target on revenue - Investing.com
1.20%
0.06%
자본화:
|
볼륨(24시간):